Diethylcarbamazine: Difference between revisions
Ostermayer (talk | contribs) |
Ostermayer (talk | contribs) |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Administration== | ==Administration== | ||
*Mechanism of Action: interferes with cyclooxygenase and lipoxygenase pathways, reducing the production of thromboxane, prostacyclin, prostaglandin and leukotrienes | *Mechanism of Action: interferes with cyclooxygenase and lipoxygenase pathways, reducing the production of thromboxane, prostacyclin, prostaglandin and leukotrienes | ||
*Dosage Forms: | *Dosage Forms: tablets | ||
*Routes of Administration: | *Routes of Administration: oral | ||
*Common Trade Names: | *Common Trade Names: N/A | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Lymphatic filariasis]]=== | |||
*''including lymphatic filariasis caused by infection with [[Wuchereria bancrofti]], [[Brugia malayi]], or [[Brugia timori]]'' | |||
{{Filariasis dec treatment}} | |||
===[[Loa Loa]]=== | |||
{{loa loa dec treatment}} | |||
===[[Mansonella streptocerca]]=== | |||
*6 mg/kg PO qDay x14 days | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Day 1: 1 mg/kg orally after meals | |||
*Day 2: 1 mg/kg orally three times daily | |||
*Day 3: 1-2 mg/kg orally three times daily | |||
*Day 4-14: 6 mg/kg/day orally divided three times daily | |||
==Special Populations== | ==Special Populations== | ||
===[[Drug pregnancy categories|Pregnancy Rating]]=== | ===[[Drug pregnancy categories|Pregnancy Rating]]=== | ||
* | *Do not use diethylcarbamazine in pregnancy. | ||
===Lactation risk=== | ===Lactation risk=== | ||
| Line 34: | Line 44: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Anaphylaxis if allergic to Hetrazan | |||
===Common=== | ===Common=== | ||
*Fever | |||
*GI distress | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 8hrs | ||
*Metabolism: | *Metabolism: Partially metabolized to diethylcarbamazine N-oxide. | ||
*Excretion: | *Excretion: | ||
Latest revision as of 13:14, 3 April 2022
Overview
Diethylcarbamazine (DEC) used globally its anti-filaricidal activity[1]
Administration
- Mechanism of Action: interferes with cyclooxygenase and lipoxygenase pathways, reducing the production of thromboxane, prostacyclin, prostaglandin and leukotrienes
- Dosage Forms: tablets
- Routes of Administration: oral
- Common Trade Names: N/A
Adult Dosing
Lymphatic filariasis
- including lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori
- Day 1: 50mg PO
- Day 2: 50mg TID
- Day 3: 100mg TID
- Days 4-21: 6mg/kg/day divided TID
Loa Loa
- Day 1: 50 mg PO PC
- Day 2: 50 mg PO TID
- Day 3: 100 mg PO TID
- Day 4-21: 9 mg/kg/day PO divided TID
Mansonella streptocerca
- 6 mg/kg PO qDay x14 days
Pediatric Dosing
- Day 1: 1 mg/kg orally after meals
- Day 2: 1 mg/kg orally three times daily
- Day 3: 1-2 mg/kg orally three times daily
- Day 4-14: 6 mg/kg/day orally divided three times daily
Special Populations
Pregnancy Rating
- Do not use diethylcarbamazine in pregnancy.
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Anaphylaxis if allergic to Hetrazan
Common
- Fever
- GI distress
Pharmacology
- Half-life: 8hrs
- Metabolism: Partially metabolized to diethylcarbamazine N-oxide.
- Excretion:
Mechanism of Action
Comments
See Also
References
- ↑ Peixoto CA et al. Anti-inflammatory effects of diethylcarbamazine: A review. European Journal of Pharmacology 734 (2014) 35–41